Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK7 | Q8TDX7 | 15/20 | 0.46 |
| ▸ | EGFR | P00533 | 4/20 | 0.44 |
| ▸ | SRC | P12931 | 4/20 | 0.44 |
| ▸ | LCK | P06239 | 2/20 | 0.43 |
| ▸ | ABL1 | P00519 | 3/20 | 0.42 |
| ▸ | ABL2 | P42684 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6861567 | 0.90 | NEK7 (0.49) | NEK7EGFRSRCLCKABL1 | |
| SCHEMBL6872025 | 0.83 | NEK7 (0.49) | NEK7 | |
| SCHEMBL2074527 | 0.79 | ABL1 (0.50) | EGFRSRCLCKABL1ABL2 | |
| SCHEMBL6867323 | 0.77 | ABL1 (0.48) | NEK7EGFRSRCLCKABL1 | |
| SCHEMBL22418417 | 0.76 | NEK7 (0.51) | NEK7EGFRSRCLCK | |
| SCHEMBL6865329 | 0.75 | RET (0.43) | NEK7EGFRSRCABL1ABL2 | |
| SCHEMBL6867388 | 0.74 | ABL1 (0.45) | NEK7EGFRSRCABL1ABL2 | |
| SCHEMBL2071828 | 0.73 | FLT3 (0.46) | EGFRSRCLCKABL1ABL2 | |
| SCHEMBL2074654 | 0.73 | IGF1R (0.60) | NEK7EGFRSRCLCKABL1 | |
| SCHEMBL6460401 | 0.73 | EIF2AK3 (0.49) | NEK7EGFRSRCLCKABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6713474-B2 | SERINE-THREONINE AND TYROSINE KINASE INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2004-03-30 | — | — | US | disclosed |
| US-20030153752-A1 | Pyrrolopyrimidines as therapeutic agents | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2003-08-14 | — | — | US | disclosed |
| EP-1114053-A1 | PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2001-07-11 | — | — | EP | disclosed |
| WO-2000017203-A1 | PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2000-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153752-A1 | Pyrrolopyrimidines as therapeutic agents | FLT1, FLT4, TFPI | NEK7 1848/4885EGFR 457/4885SRC 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.